Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 6/20 | 0.65 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.49 |
| ▸ | RAF1 | P04049 | 6/20 | 0.48 |
| ▸ | BRAF | P15056 | 6/20 | 0.48 |
| ▸ | EGFR | P00533 | 4/20 | 0.47 |
| ▸ | FLT1 | P17948 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | CSF1R | P07333 | 2/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.45 |
| ▸ | FLT3 | P36888 | 2/20 | 0.45 |
| ▸ | FLT4 | P35916 | 1/20 | 0.45 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5179191 | 0.87 | TRPA1 (0.54) | KDM1ATRPA1RAF1BRAFEGFR | |
| SCHEMBL19916574 | 0.79 | KDM1A (0.78) | KDM1ARAF1BRAFEGFRKDR | |
| SCHEMBL5177474 | 0.79 | TRPA1 (0.43) | KDM1ATRPA1RAF1BRAFEGFR | |
| SCHEMBL14814872 | 0.78 | L3MBTL1 (0.39) | KDM1AEGFR | |
| SCHEMBL14771329 | 0.77 | KDM1A (0.58) | KDM1ATRPA1RAF1BRAFEGFR | |
| SCHEMBL5177012 | 0.77 | KDM1A (0.64) | KDM1ARAF1BRAFEGFRKDR | |
| SCHEMBL1983663 | 0.77 | KDM1A (0.64) | KDM1AEGFRKDR | |
| SCHEMBL17278108 | 0.76 | KDM1A (0.73) | KDM1ARAF1BRAFEGFRKDR | |
| SCHEMBL23158502 | 0.75 | KDM1A (0.56) | KDM1ATRPA1RAF1BRAFEGFR | |
| SCHEMBL14771291 | 0.74 | TRPA1 (0.64) | KDM1ATRPA1RAF1BRAFEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233924-A1 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233924-A1 | Quinazoline derivatives | AQP1, PGF, F12 | KDM1A 2179/4885TRPA1 3713/4885RAF1 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.